Great research starts with great data.

Learn More
More >
Patent Analysis of

Stabilisation of radiopharmaceutical precursors

Updated Time 12 June 2019

Patent Registration Data

Publication Number

US10000518

Application Number

US11/721563

Application Date

18 November 2005

Publication Date

19 June 2018

Current Assignee

GE HEALTHCARE LIMITED,GE HEALTHCARE AS

Original Assignee (Applicant)

WICKSTROM, LILL TORILD,VELD, DIRK-JAN IN'T,OSBORN, NIGEL JOHN,GRIGG, JULIAN,WILSON, ANTHONY

International Classification

C07H13/04,C07H5/00,C07H5/02

Cooperative Classification

C07H5/00,C07H5/02,C07H1/00,C07H13/04

Inventor

WICKSTROM, LILL TORILD,VELD, DIRK-JAN IN'T,OSBORN, NIGEL JOHN,GRIGG, JULIAN,WILSON, ANTHONY

Patent Images

This patent contains figures and images illustrating the invention and its embodiment.

US10000518 Stabilisation radiopharmaceutical precursors 1 US10000518 Stabilisation radiopharmaceutical precursors 2 US10000518 Stabilisation radiopharmaceutical precursors 3
See all images <>

Abstract

The present invention relates to a method for improving stability of non fluoridated sugar derivatives, and in particular glucose derivatives such as 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-ß-D-mannopyranose which are used as precursors for production of radiofluoridated sugar derivatives for use in in vivo imaging procedures such as positron emission tomography (PET). The method comprises storing the non fluoridated sugar derivative in an organic solvent. The resultant formulations of the non fluoridated sugar derivative and cassettes for automated synthesis apparatus comprising the same are also claimed.

Read more

Claims

1. A method of storing 1,3,4,6-tetra-O-acetyl-2O-trifluoromethanesulfonyl-β-D-mannopyranose (mannose triflate), the method comprising dissolving mannose triflate in acetonitrile to form a solution and storing the solution in a sealed container for subsequent storage, wherein the solution consists of mannose triflate and acetonitrile, wherein the stability of the mannose triflate stored in the acetonitrile is better than the stability of mannose triflate stored without the acetonitrile, and wherein the acetonitrile has a water content between 100 ppm and 50000 ppm.

2. The method of claim 1, wherein the concentration of the mannose triflate in the solution is between 10 mg/mL to 18 mg/mL.

3. The method of claim 1, wherein the sealed container is a septum-sealed vial.

4. The method of claim 1, wherein the acetonitrile has a water content of approximately 600 ppm.

5. The method of claim 1, wherein the acetonitrile has a water content between 100 ppm and 600 ppm.

Read more

Claim Tree

  • 1
    1. A method of storing 1,3,4,6-tetra-O-acetyl-2O-trifluoromethanesulfonyl-β-D-mannopyranose (mannose triflate), the method comprising
    • dissolving mannose triflate in acetonitrile to form a solution and storing the solution in a sealed container for subsequent storage, wherein the solution consists of mannose triflate and acetonitrile, wherein the stability of the mannose triflate stored in the acetonitrile is better than the stability of mannose triflate stored without the acetonitrile, and wherein the acetonitrile has a water content between 100 ppm and 50000 ppm.
    • 2. The method of claim 1, wherein
      • the concentration of the mannose triflate in the solution is between 10 mg/mL to 18 mg/mL.
    • 3. The method of claim 1, wherein
      • the sealed container is a septum-sealed vial.
    • 4. The method of claim 1, wherein
      • the acetonitrile has a water content of approximately 600 ppm.
    • 5. The method of claim 1, wherein
      • the acetonitrile has a water content between 100 ppm and 600 ppm.
See all independent claims <>

Description

This application is a filing under 35 U.S.C. 371 of international application number PCT/GB2005/004448, filed Nov. 18, 2005, which claims priority to application number 0428020.2 filed Dec. 22, 2004, in Great Britain the entire disclosure of which is hereby incorporated by reference.

The present invention relates to a method for improving stability of non fluoridated sugar derivatives, and in particular glucose derivatives which are used as precursors for production of radiofluoridated sugar derivatives for use in in vivo imaging procedures such as positron emission tomography (PET). The invention further includes formulations of non fluoridated sugar derivatives, and cassettes for automated synthesis apparatus comprising the same.

Non fluoridated sugar derivatives such as 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-β-D-mannopyranose (commonly known as mannose triflate) are currently supplied commercially as dry powders and need to be stored at sub-ambient temperatures to ensure stability over a reasonable period, the shelf life of dry powder mannose triflate is 6 months at 5° C. In the context of an automated radiofluoridation system such as TracerLab MX (Coincidence Technologies), this means that the mannose triflate has to be stored separately from the other reagents and assembled into the cassette by the operator prior to running the radiofluoridation process. Therefore, there exists the need for a method to improve stability of non fluoridated sugar derivatives such as mannose triflate to improve shelf-life and preferably allow storage at ambient temperature, for example, in the same package as the other reagents or as part of a preassembled cassette.

The present inventors have surprisingly found that by storing a non fluoridated sugar derivative, such as mannose triflate in an organic solvent rather than as a dry powder, the stability is improved. This runs contrary to expectations as normally degradation would be expected to occur more quickly in solution. Presentation of a non fluoridated sugar derivative, such as mannose triflate in an organic solvent has the further advantage that, being already in solution, dissolution of the non fluoridated sugar derivative, such as mannose triflate prior to performing radiofluoridation can be avoided which may be particularly advantageous in an automated radiochemistry operation.

Therefore, according to one aspect of the invention, there is provided a method for improving stability of a non fluoridated sugar derivative which comprises storage of said non fluoridated sugar derivative in a solvent in a sealed container.

The solvent used in the method may be an aprotic solvent (as defined more fully below) or a protic solvent. Suitable protic solvents include C1-8alcohols, for example methanol, ethanol, isopropanol, isobutanol, acetone or octanol. The solvent used may be dry, meaning having a water content of 10000 ppm or less, suitably 1000 ppm or less, more suitably less than 600 ppm, and preferably less than 100 ppm.

In one aspect of the invention, it is advantageous that the non fluoridated sugar derivative is stored in the same solvent which will be used subsequently in the fluoridation reaction. This avoids an extra step of solvent removal before fluoridation. Therefore, according to a further aspect of the invention, there is provided a method for improving stability of a non fluoridated sugar derivative which comprises storage of said non fluoridated sugar derivative in an aprotic solvent in a sealed container.

Suitable aprotic solvents for this purpose include acetonitrile, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dioxan, 1,2-dimethoxyethane, sulfolane and N-methylpyrrolidinone. However, acetonitrile has been found to be a particularly suitable solvent for storage. The aprotic solvent used may be dry, meaning having a water content of 1000 ppm or less, suitably less than 600 ppm, and preferably less than 100 ppm. In an alternative embodiment of the invention, the aprotic solvent used may have a water content of between 1000 ppm and 50000 ppm, suitably a water content of 1000 ppm to 15000 ppm, more suitably 1500 ppm to 7000 ppm or 1800 ppm to 7000 ppm, and more suitably 1500 ppm to 7000 ppm or 1800 ppm to 2500 ppm. Using an aprotic solvent with such a controlled water content has the added advantage that the non fluoridated sugar derivative may be presented in solution having the optimum water content for performing a subsequent radiofluoridation reaction, thus avoiding the need to adjust the water content, for example by a drying step or by addition of further water or solvent.

As used herein, the term “ppm”, when describing water content of a given solvent, means μgram water/gram.

Suitably, the non fluoridated sugar derivative is present in the solvent, suitably an aprotic solvent at a concentration suited for performing a subsequent radiofluoridation reaction, for example from 0.1 mg/ml to 50 mg/ml, more suitably 5 mg/ml to 25 mg/ml, even more suitably 10 mg/ml to 18 mg/ml. In one particular embodiment, the non fluoridated sugar derivative is present in the solvent, suitably an aprotic solvent at a concentration of 15 mg/ml. In a further embodiment, the non fluoridated sugar derivative is present in the solvent, suitably an aprotic solvent at a concentration of 17.5 to 21.5 mg/ml.

Suitable sealed containers are those which do not interact with the solvent or with the non fluoridated sugar derivative, optionally permit maintenance of sterile integrity, plus optionally an inert headspace gas (e.g. nitrogen or argon), whilst also optionally permitting addition and withdrawal of solutions by syringe. Such containers include liquid-tight or gas-tight jars, flasks, ampoules and vials, the seal being provided by a liquid-tight or gas-tight closure such as a lid, stopper, or septum. A preferred such container is a septum-sealed vial, wherein the gas-tight closure is crimped on with an overseal (typically of aluminium). Such containers have the additional advantage that the closure can withstand vacuum if desired for example to change the headspace gas or degas solutions and can withstand an overpressure, for example to aid in the removal of the solution from the container.

Using the methods described herein, the non fluoridated sugar derivative may be stored for extended periods of 2 days or more, for example up to 18 months, suitably up to 6 months, more suitably for up to 8 weeks, at temperatures at or below ambient, for example at −10° C. to 35° C., suitably 10° C. to 35° C. As mentioned above, storage at ambient temperature is particularly convenient.

In the alternative, there is provided a formulation of a non fluoridated sugar derivative comprising said non fluoridated sugar derivative, and a solvent in a sealed container as described hereinbefore. The solvent present in the formulation may be an aprotic solvent or a protic solvent as described above.

In the alternative, there is further provided a formulation of a non fluoridated sugar derivative comprising said non fluoridated sugar derivative, and an aprotic solvent in a sealed container as described hereinbefore.

In the present specification, the term “non fluoridated sugar derivative” refers to a polysaccharide, oligosaccharide, disaccharide or monosaccharide sugar in which one of the OH groups is replaced by a leaving group and the other OH groups of the sugar are each optionally protected with a suitable protecting group. Such non fluoridated sugar derivatives are suitably derivatives of monosaccharides such as glucose, fructose, ribose, arabinose, mannose or galactose, most suitably glucose derivatives. Particular non fluoridated sugar derivatives used in the invention are those of formula (I):

wherein L is a leaving group and P1 to P4 are each a suitable protecting group.

Suitable protecting groups which may be present in the non fluoridated sugar derivatives used in the invention are well known in the art and are described, for example, in “Protecting Groups in Organic Synthesis”, Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons Inc. The particular protecting group chosen will depend upon the intended process for preparation of the fluoridated product but, for example, the hydroxy groups may be protected by conversion to alkyl or aromatic esters, for example by reaction with an alkanoyl chloride such as acetyl chloride. Alternatively, hydroxy groups may be converted to ethers, for example alkyl or benzyl ethers. Preferably, the protecting groups P1 to P4 are each an acyl group.

Suitable leaving groups are also well known in the art and include arylsulphonates such as toluene sulfonate, haloalkylsulphonates, and alkylsulphonates such as methane sulfonate. It is particularly preferred, however, that the leaving group is a trifluoromethane sulfonate (triflate) group.

A particularly preferred non fluoridated sugar derivative is 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-β-D-mannopyranose, commonly referred to as “mannose triflate”. Mannose triflate is a commercially available non fluoridated sugar derivative which is used as a precursor for synthesis of 2-[18F]fluoro-D-glucose ([18F]FDG) via the protected intermediate 2-fluoro-1,3,4,6-tetra-O-acetyl-D-glucose (tetraacetylfluorodeoxyglucose or pFDG).

As would be apparent to a person skilled in the art, a formulation according to the invention may optionally contain further ingredients such as buffers; pharmaceutically acceptable solubilisers (e.g. cyclodextrins or surfactants such as Pluronic, Tween or phospholipids); pharmaceutically acceptable stabilisers or antioxidants (such as ascorbic acid, gentisic acid orpara-aminobenzoic acid). And such ingredients may be added as part of a method according to the invention. However, presence of such ingredients is avoided where possible so that the radiofluoridated sugar derivative may be produced in as pure a form as possible for subsequent use in an in vivo imaging procedure. Therefore, formulations and methods as described herein in which the non fluoridated sugar derivative and solvent are present in the sealed container without further ingredients.

Radiotracers, such as [18F]FDG are now often prepared on an automated radiosynthesis apparatus using nucleophilic radiofluoridation chemistry with 18F, based on the reagent Kryptofix™ 2.2.2. There are several examples of such apparatus commercially available, including Tracerlab MX (Coincidence Technologies SA) and Tracerlab FX (Nuclear Interface GmbH). Such apparatus commonly comprises a cassette, often disposable, in which the radiochemistry is performed, which is fitted to the apparatus in order to perform a radiosynthesis. The cassette normally includes fluid pathways, a reaction vessel, and ports for receiving reagent vials as well as any solid-phase extraction cartridges used in post-radiosynthetic clean up steps.

A formulation of a non fluoridated sugar derivative as described herein may be housed in a disposable or removable cassette designed for use with the automated synthesis apparatus. Therefore, the invention further provides a cassette for an automated synthesis apparatus comprising a formulation of a non fluoridated sugar derivative comprising said non fluoridated sugar derivative, and a solvent in a sealed container as described hereinbefore. As demonstrated herein, the improved stability of the non fluoridated sugar derivative when stored as a formulation according to the invention means that the cassette can be provided complete with all of the reagents required for the fluoridation reaction, except for the radiofluoride, and the cassette can be stored at ambient temperature thus avoiding the need for refrigeration.

The invention is illustrated by way of the examples below, in which the following abbreviations are used:

  • MT or mannose triflate: 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-β-D-mannopyranose.
  • HPLC: high performance liquid chromatography
  • IR: infrared spectrometry
  • UV: ultraviolet
  • RCP: radiochemical purity
  • pFDG: 2-fluoro-1,3,4,6-tetra-O-acetyl-D-glucose

EXAMPLE 1: STABILITY OF MANNOSE TRIFLATE IN DRY ACETONITRILE

With reference to the Figures:

FIG. 1: HPLC-UV chromatogram of Mannose Triflate from ABX (solid material) at start.

FIG. 2: HPLC-UV chromatogram of Mannose Triflate from ABX (dissolved in acetonitrile) at start.

FIG. 3: HPLC-UV chromatogram of Mannose Triflate from ABX (solid material) stored for 2 weeks at 50° C.

FIG. 4: HPLC-UV chromatogram of Mannose Triflate from ABX (dissolved in acetonitrile) stored for 2 weeks at 50° C.

Materials:

Acetonitrile (MeCN): VWR/Merck, 4 L, water content approximately 600 ppm.

Mannose triflate ABX: Ultra-pure quality 1 g units,

Vials: Fiolax 5 ml Glass vials (13 mm), Munnerstædter.

Stoppers: West 4432/50 gray 13 mm, Teflon coated.

Caps: Helvoet Pharma

EXPERIMENTAL

Glass vials to be used are dried before use in a Lytzen heat sterilizer at 210° C. for 5 hours. Stoppers are not treated in any way.

2.0 g Mannose triflate was weighed into an Erlenmeyerflask and dissolved in 133 ml dry acetonitrile to yield an acetonitrile solution in an extraction hood. Dissolution was rapid, solid disappeared as soon as it came in contact with the acetonitrile.

Dispensing:

This solution was dispensed using a 10 ml glass volumetric cylinder into vial samples of approx. 4.2-4.4 ml.

Control samples of mannose triflate (without solvent) under air and under nitrogen were also prepared.

Filled and capped units are kept in storage at 25° C. and 50° C. in thermally controlled cabinets for set periods of time at which “pull points” a vial was removed from storage and subjected to the testing outlined below.

Test Methods Used:

Non-radioactive methods (cold) performed:

    • Appearance/organoleptic test, all pull points
    • Purity by HPLC-UV, all pull points
    • 19F-NMR, all pull points
    • Water content analysis, at time zero.

HPLC Method: octadecylsilyl silica gel (5 μm) column (Hichrom Nucleosil 100-5C18), temperature 25° C.; injection volume 20 μl; mobile phase of water acetonitrile gradient, 1 ml/min. Detection by spectrophotometer at 220 nm.

Radioactive methods (hot) performed: Radiolabelling with 18F in a glassy carbon reactor (all pull points). Each dry sample of mannose triflate (20 mg) is dissolved in dry acetonitrile (1.6 ml). For the mannose triflate stored in acetonitrile, an aliquot (3.3 ml) was removed and diluted to 4.0 ml with acetonitrile and 1.6 ml of this solution was used in the radiolabelling test. For the samples taken after 2 weeks storage at 50° C., a 1.6 ml sample of the mannose triflate solution was used directly without further dilution. In all cases, the radiolabelling was performed after drying an 18F solution of Kryptofix 2.2.2 (19.4 mg), potassium carbonate (41.0 mg), acetonitrile (0.32 ml) and water (0.04 ml) for 4 minutes at 80° C. before adding the test solution of mannose triflate in acetonitrile. The labelling reaction was carried out at 80° C. for 4 minutes in a glassy carbon reactor.

Results:

HPLC-UV traces for the solid mannose triflate control experiment and the acetonitrile solution of mannose triflate are shown in FIGS. 1 and 2 respectively. Mannose triflate elutes at 32.5 minutes.

After 2 weeks storage at 50° C., all samples of mannose triflate stored as dry powder were black and smelled strongly of acetic acid. No radiolabelling was attempted, IR showed that the material was no longer mannose triflate. The HPLC-UV trace is shown in FIG. 3, no mannose triflate was detected.

After 2 and 4 weeks storage at 50° C., the solutions in acetonitrile however, were still colourless and looked unchanged. Results from HPLC-UV showed one peak indicating no degradation of MT (FIG. 4).

Results from radiolabelling in the glassy carbon reactor at time zero and after storage for different periods at 50° C. are shown in table 1.


TABLE 1
Storage Time
MT
Acetonitrile
pFDG RCP
Sample
(weeks)
(mg)
(ml)
%
Control (air)
0
20
1.6
87
Control (air)
0
20
1.6
86
Control (N2)
0
20
1.6
82
Control (N2)
0
20
1.6
93
MT/acetonitrile
0
20
1.6
91
(15 mg/ml)
MT/acetonitrile
0
20
1.6
92
(15 mg/ml)
MT/acetonitrile
2
24
1.6
86
(15 mg/ml)
MT/acetonitrile
2
24
1.6
85
(15 mg/ml)
MT/acetonitrile
3
20
1.6
65
(15 mg/ml)
MT/acetonitrile
3
20
1.6
90
(15 mg/ml)
MT/acetonitrile
4
20
1.6
88
(15 mg/ml)
MT/acetonitrile
4
20
1.6
90
(15 mg/ml)
MT/acetonitrile
8
20
1.6
76
(15 mg/ml)
MT/acetonitrile
8
20
1.6
95
(15 mg/ml)

Conclusion:

The combination of good labelling and good chemical stability by HPLC even after 8 weeks at 50° C. leads to the conclusion that a clear stabilisation has been achieved by dissolving MT in acetonitrile.

EXAMPLE 2: STABILITY OF MANNOSE TRIFLATE IN ACETONITRILE/WATER

Using similar method to Example 1, the stability of mannose triflate in acetonitrile with water at level of approximately 725, 1450, and 2500 ppm was evaluated.

Results from radiolabelling in the glassy carbon reactor at time zero and after storage for different periods at 50° C. are shown in table 2.


TABLE 2
Water
Content
of MT
Storage
solution
Time
Acetonitrile/
pFDG
Sample
(ppm)
(weeks)
MT (mg)
water(ml)
RCP %
MT/acetonitrile
2435
0
20
1.6
90
(15 mg/ml)
MT/acetonitrile
2435
0
20
1.6
78
(15 mg/ml)
MT/acetonitrile
1402
0
20
1.6
93
(15 mg/ml)
MT/acetonitrile
725
0
20
1.6
89
(15 mg/ml)
MT/acetonitrile
725
0
20
1.6
92
(15 mg/ml)
MT/acetonitrile
2499
2
20
1.6
91
(15 mg/ml)
MT/acetonitrile
2499
2
20
1.6
76
(15 mg/ml)
MT/acetonitrile
1450
2
20
1.6
94
(15 mg/ml)
MT/acetonitrile
1450
2
20
1.6
91
(15 mg/ml)
MT/acetonitrile
2524
4
20
1.6
96
(15 mg/ml)
MT/acetonitrile
2524
4
20
1.6
87
(15 mg/ml)
MT/acetonitrile
1470
4
20
1.6
87
(15 mg/ml)
MT/acetonitrile
1470
4
20
1.6
87
(15 mg/ml)

COMPARATIVE EXAMPLE: STABILITY OF DRY POWDER MANNOSE TRIFLATE

Dry powder mannose triflate was stored in vials at different temperatures and for different time periods.

Radiolabelling Method

A solution of potassium carbonate (41 mg of potassium carbonate in 40 μl water) was added to a glassy carbon reactor and then a solution of kryptofix 222 (19.4 mg in 320 μl) was added separately. Then a solution of 18-fluoride in water (0.05 ml) was added and the solution dried by heating to 80° C. for 4 mins with a flow of dry nitrogen (at 0.3 liters/min). A solution of 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-β-D-mannopyranose (20 mg in 1.6 ml dry acetonitrile) was then added and the reaction heated for a further 4 minutes at 80° C. The reaction was then cooled to 50° C. and a sample removed for analysis by ITLC (Instant thin layer chromatography) on TLC aluminium sheets silica gel 60 F254 eluting with 95% acetonitrile, 5% water. The radiochemical purity was calculated from the ratio of 1,3,4,6-tetra-O-acetyl-2-fluoro-β-D-mannopyranose to the total of the sugar and free fluoride (the sole two components from the reaction). Results of the radiolabelling are shown in Table 3.


TABLE 3
Storage Conditions and time
% RCP
0 days under air
87
0 days under air
86
1 day @ room temperature under dry N2
82
1 day @ room temperature under dry N2
93
127 days @ 25° C. under air
1
5 days @ 50° C. under air.
5

The data support significant instability of the mannose triflate at room temperature which is much worse when heated to 50° C. The mannose triflate soon becomes black at elevated temperatures and becomes increasingly difficult to dissolve in acetonitrile.

Read more
PatSnap Solutions

Great research starts with great data.

Use the most comprehensive innovation intelligence platform to maximise ROI on research.

Learn More

Patent Valuation

$

Reveal the value <>

22.21/100 Score

Market Attractiveness

It shows from an IP point of view how many competitors are active and innovations are made in the different technical fields of the company. On a company level, the market attractiveness is often also an indicator of how diversified a company is. Here we look into the commercial relevance of the market.

100.0/100 Score

Market Coverage

It shows the sizes of the market that is covered with the IP and in how many countries the IP guarantees protection. It reflects a market size that is potentially addressable with the invented technology/formulation with a legal protection which also includes a freedom to operate. Here we look into the size of the impacted market.

59.07/100 Score

Technology Quality

It shows the degree of innovation that can be derived from a company’s IP. Here we look into ease of detection, ability to design around and significance of the patented feature to the product/service.

85.0/100 Score

Assignee Score

It takes the R&D behavior of the company itself into account that results in IP. During the invention phase, larger companies are considered to assign a higher R&D budget on a certain technology field, these companies have a better influence on their market, on what is marketable and what might lead to a standard.

21.89/100 Score

Legal Score

It shows the legal strength of IP in terms of its degree of protecting effect. Here we look into claim scope, claim breadth, claim quality, stability and priority.

Citation

Patents Cited in This Cited by
Title Current Assignee Application Date Publication Date
Macrocyclic carbamate immunomodulators ABBOTT LABORATORIES 14 March 1994 29 September 1994
MASCARA COMPRENANT UN COMPOSE ALKYLPOLYGLYCOSIDE ET/OU UN PR PRODUIT O-ACYE DU GLUCOSE L'OREAL 17 December 2003 24 June 2005
Apparatus and process for preparing radioisotope-labeled reagent NAKAZAWA; NOBUHIKO 27 February 1996 02 June 1998
Gelatinous manicure eliminating agent KAO CORP 02 June 1987 12 December 1988
Method for the production of pentopyranosyl nucleosides NANOGEN RECOGNOMICS, GMBH. 18 January 2001 08 April 2003
See full citation <>

More like this

Title Current Assignee Application Date Publication Date
在性功能障碍治疗中用作多巴胺激动剂的吗啉衍生物 辉瑞大药厂 02 December 2003 06 February 2008
Process for obtaining 4,1,6'-trichloro-4,1,'6-trideoxy-gal ceta saccharrose TATE & LYLE PATENT HOLDINGS LTD 16 December 1980 31 October 1986
A complex of a glucopyranosyl derivative and preparation method and use thereof SUNSHINE LAKE PHARMA CO., LTD. 28 November 2016 01 June 2017
Benzofuran-Derivate MERCK PATENT GMBH 05 March 1999 21 May 2015
Process for the preparation of a furfural derivative comprising neutralizing an acid reaction mixture FURANIX TECHNOLOGIES B.V. 01 July 2016 05 January 2017
Glucose dehydrogenase TOYO BOSEKI KABUSHIKI KAISHA 09 January 2009 18 January 2011
Acetic acid derivatives and processes for their production IMPERIAL CHEM IND LTD 28 December 1973 27 November 1974
Diarylfluorbutadien-Derivate MERCK PATENT GMBH 20 January 2001 26 June 2014
Process for production of piperidine derivatives AMRI BOTHELL RESEARCH CENTER, INC.,ALBANY MOLECULAR RESEARCH, INC.,AMRI BURLINGTON, INC.,AMRI RENESSELAER, INC. 15 September 2006 16 March 2010
PROCEDIMIENTO DE FLUORACION PARA LA SINTESIS DE 2-(18F)FLUORO-2-DESOXI-D-GLUCOSA. GE HEALTHCARE LIMITED 18 November 2005 26 October 2010
Process for the preparation of SGLT inhibitor compounds INDOCO REMEDIES LIMITED 09 February 2016 18 August 2016
Process for the production and isolation of 5-hydroxymethylfurfural NOVAMONT S.P.A. 16 October 2015 21 April 2016
Process for the preparation of perhydroquinoxaline derivatives DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL 17 November 2015 26 May 2016
Process for the production of acetic acid BP CHEMICALS LIMITED 08 June 2017 21 December 2017
Process for the production of ezetimibe and intermediates used in this process RICHTER GEDEON NYRT. 18 December 2006 27 August 2009
Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof SUNTORY LIMITED,TAKEMOTO, NAOHIRO,ANNOURA, HIROKAZU,MURAYAMA, NORIHITO 13 April 2001 13 June 2002
Acid mediated deacylation of 6-0-trichlorogalactosucrose to trichlorogalactosurecrose V.B. MEDICARE PVT. LTD. 17 October 2006 25 March 2009
Process for preparing pure allyl protected KETO derivative IND-SWIFT LABORATORIES LIMITED 30 March 2017 05 October 2017
Method for enzymatic conversion of d-glucose into d-fructose via d-sorbitol ANNIKKI GMBH 18 May 2017 30 November 2017
Pyridine derivative IMPERIAL CHEMICAL INDUSTRIES PLC 23 August 1988 22 March 1989
See all similar patents <>

More Patents & Intellectual Property

PatSnap Solutions

PatSnap solutions are used by R&D teams, legal and IP professionals, those in business intelligence and strategic planning roles and by research staff at academic institutions globally.

PatSnap Solutions
Search & Analyze
The widest range of IP search tools makes getting the right answers and asking the right questions easier than ever. One click analysis extracts meaningful information on competitors and technology trends from IP data.
Business Intelligence
Gain powerful insights into future technology changes, market shifts and competitor strategies.
Workflow
Manage IP-related processes across multiple teams and departments with integrated collaboration and workflow tools.
Contact Sales
Clsoe
US10000518 Stabilisation radiopharmaceutical precursors 1 US10000518 Stabilisation radiopharmaceutical precursors 2 US10000518 Stabilisation radiopharmaceutical precursors 3